May 29, 2013, 07.50 PM | Source: CNBC-TV18
Ashu Madan, president of core client group at Religare Securities advised buying Dishman Pharma at current levels. In short-term, the stock can go up by 10-15 percent, feels Madan.
Ashu Madan (more)
COO, Religare Capital | Capital Expertise: Equity - Technical ,Equity - Fundamental
“In short-term one might get 10-15 percent return soon. So in any case if somebody can hold it for longer it would be better, but the current price at which it is hovering around is a good price to buy,” Madan said.
Systematix is bullish on Dishman Pharma has recomm
Ashwani Gujral of ashwanigujral.com is of the view
Dishman Pharmaceuticals and Chemicals today report
Dishman Pharmaceuticals and Chemicals has informed
Dishman Pharmaceuticals has informed that a meetin